Literature DB >> 29150279

Resolution of recurrent tonsillitis in a non-smoker who became a vaper. A case study and new hypothesis.

Joanna Astrid Miler1, Peter Hajek2.   

Abstract

BACKGROUND: Evidence concerning the impact of vaping on respiratory infections remains contradictory. Cell and animal studies suggested that vaping may increase vulnerability to respiratory infections, but human data do not confirm this concern. CASE
PRESENTATION: We present a case of a never-smoker who became a vaper and after a few months of e-cigarette use experienced a complete resolution of chronic tonsillitis and a marked improvement in tonsilloliths.
CONCLUSIONS: As this is a never-smoker, the improvements cannot be attributed to smoking cessation. One possible explanation is that the improvement was due to antimicrobial properties of propylene glycol. The hypothesis could be tested by a trial of zero-nicotine e-cigarettes in patients with recurrent bacterial throat infection.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29150279     DOI: 10.1016/j.mehy.2017.09.006

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  3 in total

1.  Health practitioners should caution about misinformation and association of adverse effects of electronic cigarette use and COVID-19.

Authors:  Eric K Soule; Farrah Kheradmand; Thomas Eissenberg
Journal:  Prev Med Rep       Date:  2020-11-25

Review 2.  A scoping review of studies on the health impact of electronic nicotine delivery systems.

Authors:  Cother Hajat; Emma Stein; Saran Shantikumar; Raymond Niaura; Pietro Ferrara; Riccardo Polosa
Journal:  Intern Emerg Med       Date:  2021-10-12       Impact factor: 3.397

Review 3.  A Systematic Literature Review of E-Cigarette-Related Illness and Injury: Not Just for the Respirologist.

Authors:  Anna Tzortzi; Melpo Kapetanstrataki; Vaso Evangelopoulou; Panagiotis Beghrakis
Journal:  Int J Environ Res Public Health       Date:  2020-03-27       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.